Release Date: August 14, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you provide metrics on the progress in removing compounded cantharidin and the expected timeline for resolution? Also, when do you expect stocking to normalize? A: Ted White, CEO, explained that the last shipment of compounded cantharidin was in April 2024, with a six-month shelf life, so it should bleed out by the second half of the year. Terry Kohler, CFO, added that they expect inventory to normalize by early 2025 as demand grows.
Q: What is the pathway forward for VP-315 in basal cell carcinoma, considering the current surgical treatment paradigm? A: Gary Goldenberg, CMO, stated that VP-315 has shown a 51% complete histologic clearance rate and a 71% reduction in tumor size for residual tumors in Phase 2 trials. This suggests it could be used between biopsy and surgery, potentially reducing the need for surgery or the size of surgical interventions.
Q: How are you prioritizing efforts to accelerate YCANTH's market presence, and what is the impact of same-day treatment and prior authorization barriers? A: Ted White, CEO, emphasized removing prior authorizations, especially in managed Medicaid, and enhancing the co-pay program. They are also leveraging partnerships with Cencora and Vizient to improve market penetration and streamline processes for physicians.
Q: Are you seeing any new compounded cantharidin entering the market after the settlement with Dormer Labs? A: Ted White, CEO, confirmed that there is no new compounded cantharidin entering the market, though some Dormer inventory is still being used up.
Q: With the recent approval of a competitor's product, how do you view the competitive landscape for YCANTH? A: Ted White, CEO, acknowledged the approval of ZELSUVMI but sees it as beneficial, as it increases awareness of molluscum contagiosum treatment. He believes cantharidin remains the gold standard.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。